Background Uric acid (UA) is associated with high blood pressure in adolescents and with left ventricular hypertrophy (LVH) and cardiovascular disease (CVD) in adults. We sought to determine if UA is independently associated with CVD risk factors and left ventricular mass (LVM) over time in hypertensive youth. Methods This was a 1-year prospective observational study of hypertensive children aged 3-19 years. Cross-sectional and longitudinal associations of serum UA with CVD risk factors and LVM were explored. Results Of the 49 children who completed both the baseline and 12-month assessments, at baseline the mean age was 13.8 years and mean UA was 5.5 mg/dL; 24 % had elevated UA, 51 % were overweight/obese and 39 % had LVH. Measures of adiposity, low high-density lipoprotein cholesterol, high-sensitivity C-reactive protein, LVM and LVH were all significantly associated with elevated UA at baseline, but not with change over time. Each 1 mg/dL increase in baseline UA was associated with a 2.5 g/m 2.7 increase in the LVM index at follow-up (95 % confidence interval 0.64, 4.39; p= 0.01); after adjustment for age, sex, race, body mass index zscore, change in UA, time, blood pressure and medication use, this association was no longer significant. Conclusions Hypertensive children with elevated UA have a higher prevalence of obesity-related CVD risk factors. Among hypertensive children, UA may be a marker of adiposity and not an independent CVD risk factor.
Introduction
Cardiovascular disease (CVD) remains the leading cause of mortality worldwide [1] . Primary prevention and treatment of traditional CVD risk factors is the mainstay of efforts aimed at diminishing the morbidity and mortality related to CVD in adults. As CVD risk factors are increasingly prevalent among children and adolescents, identifying at risk children would aid in minimizing the burden of adult CVD. In fact, the American Heart Association's recent policy statement emphasizes that CVD risk factor prevention should begin in childhood [2] .
In recent years, the prevalence of hyperuricemia has increased in children [3] . Adult studies have described an association between serum uric acid (UA) and increased CVD mortality [4] [5] [6] independent of traditional CVD risk factors [7] . A common precursor to adult CVD events is left ventricular hypertrophy (LVH) [8] . This pathological remodeling of the heart is also associated with elevated UA in adults [9, 10] . Further, when LVH and hyperuricemia are present together, the risk for CVD events increases substantially [6] .
While there is some evidence that lowering UA may reduce blood pressure (BP) in adolescents [11] , it is not currently a therapeutic target for hypertension treatment in these patients nor in adults. Further, the longitudinal association of serum UA with CVD risk factors and target organ damage in hypertensive children has not been well described. We therefore sought to investigate the association of UA with CVD risk factors and LVH, defined as increased left ventricular mass index (LVMI). We also explored the hypothesis that BP mediates the relationship between serum UA and LVMI over time.
Methods Study subjects and study design
This was a secondary analysis of data obtained during a 1-year prospective observational study designed to evaluate the impact of CVD risk factors on regression of LVH over time among hypertensive children. Participants were recruited from an urban pediatric subspecialty clinic between August 2010 and June 2013. To be eligible, children had to be 3-21 years old and diagnosed with hypertension according to established guidelines prior to the study visit. Children with chronic kidney disease≥ stage 2, congenital heart disease or cancer were ineligible. Informed consent and assent were obtained at the baseline visit. The Institutional Review Board at Johns Hopkins University School of Medicine approved this study.
Data collection

Anthropometric measurements
At both the baseline and 12-month follow-up visits, children had their height measured with a stadiometer to the nearest 0.1 cm and their weight with light clothing measured by a calibrated standing balance scale to the nearest 0.1 kg. Body mass index (BMI) was then calculated (kg/m 2 ). Height, weight, BMI percentiles and z-scores were calculated using the Centers for Disease Control and Prevention normative growth data [12] [13] [14] . Children were categorized as normal weight (BMI percentile <85 %) or overweight/obese (BMI percentile ≥85 %). Waist circumference was measured 1 cm above the patients' navel on exhale using a Gulick tape measure which applies known tension. Hip circumference was measured at the widest girth around the hip and buttocks in triplicate; the averages were categorized as above/below the respective age/sex/race-specific 90th percentile [15] .
BP measurements
After 5 min of rest, a research nurse obtained three clinic BP measurements with an aneroid sphygmomanometer, 30 s apart. BP cuffs were chosen based on mid-arm circumference. Individuals responsible for BP measurement underwent training and passed yearly certification evaluations. The three BP measurements were averaged to provide one overall measurement for each visit.
Children also underwent 24-h ambulatory BP monitoring (ABPM) using an oscillometric device (Spacelabs 90210; SpaceLabs Inc., Redmond, WA) according to published guidelines [16] . Every 20 min an oscillometric BP was obtained. Awake and sleep times were determined by diary.
To allow for comparison of degree of BP elevation among all participants, BPs were indexed by dividing the average systolic (and diastolic) BP by the corresponding 95th percentile systolic (and diastolic) BP [16, 17] . For participants aged ≥18 years, 140 mmHg was used as the denominator for systolic BP index (SBPi) and 90 mmHg was used for the denominator for diastolic BP index (DBPi) for both clinic and awake BP measurements. A BP index of ≥1 indicates an elevated BP; each 0.1 increment above (or below) 1 represents a 10 % increase (or decrease) in BP from the BP threshold for hypertension.
Laboratory assessment
A random blood sample and a 24-h urine collection were obtained at both the baseline and 12-month follow-up visits for analysis of UA (mg/dL), highsensitivity C-reactive protein (hsCRP, mg/dL), lipids [total cholesterol, low-density lipoprotein, high-density lipoprotein (HDL), triglycerides; all mg/dL], hemoglobin A1c (%), plasma renin activity (ng/mL/h), serum aldosterone (ng/dL) and sodium concentration (mg/day). HsCRP concentration was determined using a highly sensitive immunoturbidimetric method. Hemoglobin A1c was measured by high-performance liquid chromatography. Aldosterone and plasma renin activity were measured at a Quest Diagnostics Inc. clinical testing laboratory using the liquid chromatography/tandem mass spectrometry (LC/MS/MS). Urine sodium concentration was measured using a Hitachi automated clinical chemistry analyzer (Hitachi Ltd., Tokyo, Japan).
Serum UA was determined by enzymatic spectrophotometry. Children were categorized as having elevated or normal serum UA based on the respective age/sex/race 95th percentile norms [18, 19] . All routine clinical tests, except for plasma renin activity and serum aldosterone, were performed in the Johns Hopkins Hospital clinical laboratory.
Echocardiography
Participants underwent standardized two-dimensional guided M-mode echocardiography at both the baseline and 12-month follow-up visits. Measurements were digitally recorded and read by a study cardiologist for standardization (KWH). Three diastolic measurements of the LV dimension, intraventricular septum and LV posterior wall were made and averaged.
LV mass (LVM) was calculated using the Devearaux equation [20] ). LVH was defined as a LVMI of ≥95th percentile [21] .
Statistical analysis
Cross-sectional analyses
Baseline clinical variables were compared between those with and without elevated UA at baseline. Categorical variables were compared using Fisher's exact test, and continuous variables were compared using Student's t-test for normally distributed data and Wilcoxon Rank Sum for non-normally distributed data. Linear and logistic regression were utilized to evaluate the association between continuous and categorical measurements of UA and LVMI and between UA and LVH, respectively. To evaluate whether BP mediated this potential relationship, two multivariable regression models were conducted: one adjusting for age, sex, race and BMI z-score, and another further adjusting for awake SBPi and DBPi and for whether the children were taking an angiotensin converting enzyme inhibitor (ACEi), angiotensin II receptor blocker (ARB) or diuretic.
Longitudinal analyses
To explore longitudinal associations, delta variables were created for UA, LVM, LVMI and selected risk factors by subtracting the baseline value from the 12-month follow-up value. Associations of (1) baseline exposures and (2) change in CVD risk factors over time with the change in UA over time were explored with univariate linear regression analyses. The relationship of UA at baseline with LVMI at follow-up was explored with multivariable linear regression adjusting for age at baseline, sex, race, baseline BMI z-score, change in UA and time between visits. As above, we ran an additional model further adjusting for 12-month awake SBPi, DBPi and ACEi/ARB/diuretic use at the 12-month follow-up. Finally, the same covariates were included in logistic regression analyses with LVH at follow-up as the outcome.
We also conducted several secondary exploratory analyses. We investigated for a longitudinal relationship of baseline UA with both LVMI and LVH by categorizing UA in the following ways: (1) divided into tertiles; (2) dichotomized as greater than/equal to or less than the sex-specific observed mean; (3) dichotomized as greater than/equal to or less than 5.5 mg/dL, based on evidence that a serum UA level of ≥5.5 mg/dL may be predictive of primary hypertension in otherwise healthy children [22] . As the normal values for UA and LVMI vary substantially by age, we also conducted stratified analyses to determine if age modified the effect of UA on LV size.
UA data were missing for several participants (8 at baseline; 3 at 12 months). As these missing data were due to random laboratory processing error, we conducted multiple imputation utilizing all available information on related covariates [23] . These imputed values were then analyzed as described above, with sensitivity analyses conducted to demonstrate the impact of multiple imputation compared to complete case analyses.
The statistical and database software used includes STATA 11.2 (Stata Corporation, College Station, TX) and REDCAP (Research Electronic Data Capture) hosted at Johns Hopkins University. Statistical significance for all analyses was set at two-sided p < 0.05.
Results
Cross-sectional results at baseline
Fifty-three children were enrolled and completed the baseline visit, with 49 children returning for the 12-month follow-up visit. Of the four children who did not complete all study visits, two removed themselves from the study and two were lost to follow-up. At baseline, the mean age of the 49 children who completed both baseline and 12-month assessments was 13.8 [standard deviation (SD) 3.9] years. The average length of follow-up was 12.8 (SD 2.1) months. At baseline, 51 % of these 49 children were overweight/obese, and 39 % had LVH. Baseline UA data were available for 41 children. The mean UA overall was 5.5 (SD 1.7) mg/dL, with mean UA for females being 4.7 (SD 1.2) mg/dL and for males 6.1 (SD 1.8) mg/dL (p=0.008); 24 % of participants had elevated UA. A comparison of the demographic characteristics and CVD risk factors between children with normal and elevated UA at baseline is provided in Table 1 . Children with elevated UA had more markers of adiposity than those with a normal UA; they also had lower HDL-cholesterol, higher hsCRP, greater LVM and a greater prevalence of LVH than those with normal UA. In addition, the former were older and had a higher plasma renin activity than children with normal UA. While non-significant, children with elevated UA excreted 1.4 g more sodium per day than those with normal UA (4.6 vs. 3.2 g, p=0.32). There were no statistically significant differences in sex, race, mean clinic or awake BP (mmHg or index) or LVMI between the groups. In addition, other CVD risk factors, such as birth weight, metabolic syndrome diagnosis (defined in Table 1 ) and non-HDL cholesterol, were not different between the groups. Table 2 shows the association of baseline UA with measures of LV size at baseline. In the univariate regression, each 1 mg/dL increase in UA over the baseline value was associated with an increase in LVM of 20.2 g (95 % CI 12.9, 27.5; p ; LVH, left ventricular hypertrophy = LVMI ≥ 95th percentile a Values are given as the mean ± standard deviation, as the median with the interquartile range in parenthesis or as a number with the percentage in parenthesis, as appropriate b Normal UA defined as a serum UA <95th percentile for age, race and sex using Harriet Lane Handbook cutoffs for <12 years [18] ; NHANES for 12-19 years [19] . Elevated UA is defined as ≥95th percentile c Overweight/obese defined as BMI ≥85th percentile d Metabolic syndrome defined if any three of the following were present: BMI>97th percentile; hypertriglyceridemia (triglycerides >110 mg/dL); low HDL (HDL cholesterol <40); systolic/diastolic blood pressure >90th percentile; waist circumference >90th percentile <0.001) and 1.5-fold greater odds of LVH (95 % CI 1.0, 2.3; p=0.03). However, these associations were no longer significant after adjustment for age, sex, race/ethnicity and BMI zscore, and after further adjustment for wake SBPi and DBPi and ACEi/ARB/diuretic use.
Longitudinal results
At the 12-month follow-up, mean UA was 5.7 (SD 1.6) mg/ dL, and mean change from baseline was 0.2 (SD 0.9; range −1.9, 2.3) mg/dL. Children aged <12 years at baseline experienced a greater increase in UA (0.7 mg/dL, SD 0.8) than those aged ≥12 years (−0.02 mg/dL, SD 0.8; p=0.02). The change in UA over time also differed by sex, although this difference was not statistically significant: mean increase in UA among males was 0.3 (SD 0.1) mg/dL and among females 0.1 mg/dL (SD 0.6; p=0.5).
At the 12-month follow-up, the prevalence of elevated UA, overweight/obesity and LVH was similar to the respective baseline values, with 20 % of children having elevated UA, 57 % being overweight/obese and 53 % having LVH (all p>0.05 when compared to baseline). Overall, the BMI z-score increased by 0.1 (SD 0.3; p= 0.02) from baseline. Individuals who were overweight/ obese at baseline had a lesser change in BMI z-score compared to those who were of healthy weight at baseline (0.03 (SD 0.2) vs. 0.2 (SD 0.4; p=0.09). On average, the cohort had good BP control throughout, with uncontrolled hypertension only present among 38 % of participants at baseline and 35 % at follow-up. The majority (90 %) of children were prescribed an antihypertensive medication. Seven children were on an ARB both at baseline and at the 12-month follow-up. In addition, five children were taking a diuretic at baseline and six at follow-up; only two of the children prescribed a diuretic were not also on an ACEi/ARB. Age and serum aldosterone at baseline were the only patient characteristics associated with UA over time (Table 3) .
Given the association of markers of adiposity with elevated UA at baseline, we conducted stratified analyses based on characterization as overweight/obese versus healthy weight at baseline. Compared to participants of healthy weight, overweight/obese participants at baseline had a higher serum UA (6.2 vs. 4.9 mg/dL; p=0.01) but no difference in change over time (Fig. 1) . Further, increasing BMI z-score was not associated with change in UA: participants with an increase in BMI z-score over time demonstrated a serum UA increase of 0.2 mg/dL and those with a stable/decreasing BMI z-score over time demonstrated a serum UA increase of 0.3 mg/dL (p=0.8).
In unadjusted analyses, baseline UA was positively associated with LVMI over time, with each 1 mg/dL increase over the baseline UA level being associated with a 2.5 g/m 2.7 greater LVMI at follow-up (95 % CI 0.6, 4.4; p=0.01). However, after adjustment, this association was no longer significant. Analyses with LVH as the outcome revealed similar results (Table 3) .
Exploratory secondary analyses revealed no longitudinal relationship between UA and LVMI or LVH when UA was divided into tertiles, dichotomized into greater than/equal to or less than thesex-specific observed mean or dichotomized as greater than/equal toor less than 5.5 mg/dL. In addition, stratified analyses separating children into different age groups (≥12 vs. < 12 years; ≥8 vs. <8 years) revealed similar non-significant results. 
Discussion
In this 1-year observational study of hypertensive children, we found that a quarter of children had an elevated UA and that >25 % had other comorbid CVD risk factors, most of which were related to overweight/obesity. These more traditional CVD risk factors, namely, adiposity, low HDL, hsCRP, LVM and LVH, were significantly associated with elevated UA, as were older age and variables related to the renin-angiotensin-aldosterone system (RAAS). Of these, adiposity had the strongest relationship with UA. In fact, overweight/obesity was the most prevalent CVD risk factor in our cohort, with a striking 51 % of children being overweight/obese at baseline and 57 % being overweight/obese at the 1-year follow-up assessment, despite standard of care guidance regarding weight loss and lifestyle modifications. Not only did the overweight/obese children have a higher UA overall, practically all (90 %) of those with an elevated UA were overweight/obese, a remarkable difference from the group with normal UA. Interestingly, BP was not associated with UA in either the cross-sectional or prospective analyses. Given prior research in the field [11, 22, 24] , we expected to find an independent relationship between BP and UA among the children in our study. The postulated biological mechanisms underlying this relationship have been related to UA inducing oxidative stress, activating inflammatory pathways, increasing vascular smooth muscle proliferation and endothelial dysfunction and stimulating the RAAS [25] .
The lack of an association between UA and BP in our cohort may be related to the fact that all enrolled children were being treated for hypertension; consequently, no untreated normotensive children were enrolled in the study. It may be that once BP is already elevated above normal, UA may play a lesser role in further elevating BP. In fact, our previous study that demonstrated increasing levels of UA are associated with elevated BP [26] included healthy U.S. adolescents with a wide range of BPs (normal and elevated) and not just those with elevated BP as in this cohort of children. Another possibility for the lack of an observed association is our comparatively small sample size. More studies are required to further investigate this relationship.
Despite the significant cross-sectional baseline associations, multivariable analyses revealed that serum UA was not independently associated with CVD risk factors over time, nor was it associated with LVM or LVH. There are several potential explanations for these findings. As suggested above, it may be that among hypertensive children already under treatment UA plays a lesser role in the development of target organ damage. It may also be that the cardiovascular system only exhibits notable changes after a longer exposure to elevated UA. Multiple prior studies suggest that the effect of UA in adults coursed over several years [27] , whereas we only looked at the relationship between UA, LVMI and CVD risk factors over 1 year. In fact, we noted very little change in the measured CVD risk factors over the 1-year observation period. Specifically, UA values remained similar over time as did BMI z-scores and BP. If time exposed is important in pathogenesis, then a longer period of observation in childhood, or following youth into adulthood may be necessary to discern the pathological effects of UA on CVD risk factors and endorgans. Another possibility is related to small sample size; studying more children would increase statistical power to detect an association if present. Finally, it may be that UA is merely a marker of overweight/obesity, and not an independent CVD risk factor. As such, controlling for overweight/ obesity in a multivariable analysis would necessarily diminish any observed univariate relationship.
One finding that should be highlighted is the high dietary sodium intake among all children in the cohort, and the greater intake found among those with elevated UA. The overall mean sodium intake, as ascertained by 24-h urinary excretion of sodium that estimates intake the day prior, was 3.5 g/day. This intake is similar to the mean daily intake reported from National Health and Nutrition Examination Survey data in 2012, where the average sodium intake reported by 8-to 18-year-olds was 3.4 g/day [28] . The sodium excretion by the children in our study with elevated UA was 1.4 g/day more than that of children with normal UA levels. While this difference is not statistically significant, we feel it deserves mention as it adds to the literature regarding the impact of dietary sodium on CVD risk among children. Further, our result is consistent with the adult literature which has shown higher sodium intake to be independently associated with larger increases in serum UA over time [29] .
Our study has several important limitations. First, our cohort size is small and from a tertiary care sub-specialty clinic; consequently, it may not be a general representation of all hypertensive children. Second, our 1-year observational period may be too short to detect significant associations. Furthermore, we were unable to obtain fasting insulin samples and therefore could not fully explore the relationship between UA and LVMI. Finally, as an observational study, it is possible that other unmeasured exposures and risk factors may have influenced our findings and could explain some of our results. Notwithstanding these limitations, this study benefits from the prospective analysis of change in UA over time. To our knowledge, this study is the longest follow-up in children and adolescents to look at the relationship of UA and CVD risk factors over time. In addition, the study population provided data from a racially diverse group of hypertensive children with standardized anthropometric, BP and echocardiography measurements. We were able to follow a population of hypertensive individuals who were largely free of the multiple CVD co-morbidities found in adults. This allows for a less confounded investigation into the association of UA and CVD risk factors.
In summary, CVD risk factors such as overweight/obesity, hypertension and LV hypertrophy are highly prevalent among children and adolescents. UA, a putative CVD risk factor in adults, is associated with a higher prevalence of obesityrelated CVD risk factors among hypertensive children and may play a role in CVD risk assessment. Future studies with a longer follow-up period are needed to determine if UA is merely a marker of adiposity or an independent CVD risk factor.
